Please assess the completion status of the following clinical trial:

Trial Title: Use of Percutaneous Tibial Nerve Stimulation With Solifenacin or Placebo to Treat Refractory Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older~2. history of overactive bladder~3. history of inadequate response to prior or current treatment with anti- muscarinic medication, or unacceptable side effects from higher dose of anti-muscarinic medication~4. PTNS-naive~5. willing to discontinue the use of anti-muscarinic agents for 2 weeks before start of study medication (washing out)~6. able to swallow and retain oral medication~7. able and willing to participate in the full duration of the study~8. able to read and write (health outcomes questionnaires are self-administered)and understand instructions related to study procedures and give written informed consent~9. OAB-q (items 1-8) score of 30 or higher~Exclusion Criteria:~1. presence of cardiac pacemaker and/or defibrillator~2. history of urinary retention~3. history of gastric retention~4. uncontrolled narrow angle glaucoma~5. any unstable, serious co-existing medical condition(s) including, but not limited to, myocardial infarction,coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, or cerebrovascular accident within 3 months prior to Screening visit~6. abnormal liver function test (greater than 3 times the upper limit of normal for alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], or alkaline phosphatase \[ALP\]); or bilirubin \> 3 times the upper limit of normal~7. history of any illness (including psychiatric) that, in the opinion of the investigator, might confound the results of the study or pose additional risk to the subject~8. known hypersensitivity to solifenacin~9. participation in any investigational or marketed drug trial within the 30 days prior to the first dose of study drug or any time during the study period~10. pregnancy or trying to become pregnant~11. breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PTNS and solifenacin (Type: ACTIVE_COMPARATOR): PTNS bladder neuromodulation weekly for 12 treatments; solifenacin 5 mg capsule daily for 15 weeks
- PTNS and placebo (Type: PLACEBO_COMPARATOR): PTNS bladder neuromodulation weekly for 12 treatments; placebo 1 capsule daily for 15 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).